TWST Twist Bioscience Corp
FY2025 10-K
Twist Bioscience Corp (TWST) filed its fiscal year 2025 10-K annual report with the SEC on Nov 17, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Synthetic DNA production and related biotechnological research and manufacturing
- • Strategic real estate expansion: Lease amendment adds 33,000 sq. ft. for R&D, manufacturing, and administration in South San Francisco
Management Discussion & Analysis
- • Revenue $376.6M, up 20% YoY from $313.0M, driven by NGS tools +$39.0M and synthetic genes +$20.9M
- • Gross margin 50.7% vs 42.6%, up 8.1% due to revenue growth and flat fixed manufacturing costs
Risk Factors
- • Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection
- • Geopolitical/macroeconomic risk: exposure to cyberattacks by nation-state actors risking technology theft and operational disruption
Financial SummaryXBRL
Revenue
$377M
Net Income
-$78M
Operating Margin
-36.2%
Net Margin
-20.6%
ROE
-16.4%
Total Assets
$642M
EPS (Diluted)
$-1.30
Operating Cash Flow
-$48M
Source: XBRL data from Twist Bioscience Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Twist Bioscience Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.